For those of you that may have forgotten and getting impatient with the OCC share price performance in the wider mkt downturn, bear in mind from Henry Schein's own earnings transcript we should hopefully receive some news/progression on the Striate deal at the end of this quarter:
"In this connection, we are pleased to announce the partnership between BioHorizons, Camlog and Orthocell on the Striate+ tissue membrane. This product has demonstrated positive qualities for tissue regeneration, and we are excited to be able to further differentiate our offering in this area to our customers. BioHorizons, Camlog now has exclusive global rights to this product in the dental field and a long-term supply agreement with Orthocell. And we expect to launch the product toward the end of the third quarter."
(my embolden - HSIC earnings call for the period ending June 30, 2022)
(and of course the, ever late to the party, ATI study final data this quarter)
For those of you that may have forgotten and getting impatient...
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.92M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 41.5¢ | 41.0¢ | $58.47K | 142.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40000 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 21292 | 2 |
View Market Depth
| Last trade - 11.59am 02/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |